Answers are grounded in this paper and cite their sources.
Studies show mixed results regarding mortality benefit and VT recurrence in patients with ventricular tachyarrythmias (VA) without acute coronary syndrome (ACS) who undergo coronary revascularization. The goal of this meta-analysis was to assess the effect of coronary revascularization on mortality and VA recurrence in this patient subset. Databases such as PubMed, EMBASE, and the Cochrane Library were searched from January 2000 to December 2023 for randomized controlled trials and prospective cohort studies reporting event data on mortality and VA recurrence in patients without ACS who presented with VA. Data were pooled using random effects meta-analysis. The pooled sample consisted of a total of 3,584 patients presenting with VA without ACS of whom 725 underwent coronary revascularization and 2,859 who did not undergo revascularization. There was no statistically significant difference in the mortality in the patients with VA without ACS who underwent revascularization versus those who did not. (RR: 0.84; 95% CI: 0.66 to 1.07; p = 0.16). Similarly, there was no statistically significant difference in the recurrence of VA in the patients who underwent coronary revascularization compared to those who did not. (RR: 0.87; 95% CI: 0.72 to 1.05; p = 0.15). There was no publication bias detected by examination of funnel plot and by Egger's test ( P = 0.17). In patients with sustained ventricular arrhythmia in the absence of acute coronary syndrome, revascularization does not lead to improved mortality or a decrease in the incidence of VT recurrence.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: